Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2023
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Hanne Lefrère, Kat Moore, Giuseppe Floris, et al.
NPJ Precision Oncology
|
January 28, 2025
A morphometric signature to identify ductal carcinoma in situ with a low risk of progression
Marcelo Sobral-Leite, Simon P Castillo, Shiva Vonk, et al.
International Journal of Cancer
|
August 15, 2019
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression
Malgorzata A Komor, Meike de Wit, Jose van den Berg, et al.
Oncoimmunology
|
December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.
British Journal of Cancer
|
June 29, 2022
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
Mathilde M Almekinders, Tycho Bismeijer, Tapsi Kumar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Tesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Cancers
|
December 11, 2022
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
Lilian van Wagensveld, Juliette O A M van Baal, Maite Timmermans, et al.
Cancer Cell
|
April 28, 2023
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
Stefan J Hutten, Roebi de Bruijn, Catrin Lutz, et al.
Cell Reports. Medicine
|
July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Tesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2023
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Hanne Lefrère, Kat Moore, Giuseppe Floris, et al.
NPJ Precision Oncology
|
January 28, 2025
A morphometric signature to identify ductal carcinoma in situ with a low risk of progression
Marcelo Sobral-Leite, Simon P Castillo, Shiva Vonk, et al.
International Journal of Cancer
|
August 15, 2019
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression
Malgorzata A Komor, Meike de Wit, Jose van den Berg, et al.
Oncoimmunology
|
December 8, 2018
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.
British Journal of Cancer
|
June 29, 2022
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
Mathilde M Almekinders, Tycho Bismeijer, Tapsi Kumar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Tesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Cancers
|
December 11, 2022
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
Lilian van Wagensveld, Juliette O A M van Baal, Maite Timmermans, et al.
Cancer Cell
|
April 28, 2023
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
Stefan J Hutten, Roebi de Bruijn, Catrin Lutz, et al.
Cell Reports. Medicine
|
July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Tesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Page
of 9